Red Pepper Labs

Blog

  • Comparing Sermorelin and Ipamorelin: Updated Growth Hormone Secretagogue Research for 2026

    Unveiling the Nuances: Sermorelin vs. Ipamorelin in Growth Hormone Secretagogue Research 2026

    Recent groundbreaking studies published in 2026 have shifted the scientific narrative surrounding growth hormone secretagogues (GHS), specifically Sermorelin and Ipamorelin. Contrary to previous assumptions that considered these peptides interchangeable in their role as growth hormone-releasing agents, new evidence highlights significant mechanistic and efficacy differences that could influence future research directions.

    What People Are Asking

    What are the primary differences between Sermorelin and Ipamorelin?

    Researchers and clinicians often inquire about the distinct biochemical profiles and physiological outcomes of Sermorelin and Ipamorelin. This question is central to understanding their applicability in growth hormone stimulation protocols.

    How do Sermorelin and Ipamorelin differ in their receptor binding and signaling pathways?

    Given both peptides target growth hormone release, the specificity for receptors such as the Growth Hormone Releasing Hormone receptor (GHRHr) and the Growth Hormone Secretagogue receptor (GHSR1a) explains variations in their downstream effects.

    Which peptide demonstrates greater efficacy and safety in stimulating endogenous growth hormone secretion?

    Evaluating comparative efficacy studies is crucial to delineate therapeutic potential and safety profiles, given the delicate balance required for growth hormone modulation.

    The Evidence

    Differential Receptor Targeting and Mechanisms

    Sermorelin is a truncated fragment of endogenous Growth Hormone Releasing Hormone (GHRH) comprising the first 29 amino acids, primarily acting as a GHRHr agonist. It stimulates the hypothalamic-pituitary axis, resulting in increased growth hormone (GH) synthesis and release from somatotroph cells.

    Ipamorelin, in contrast, is a synthetic pentapeptide that selectively mimics ghrelin and acts as a growth hormone secretagogue receptor (GHSR1a) agonist. This receptor engagement bypasses the hypothalamic GHRH signaling, directly stimulating pituitary somatotrophs to release GH.

    Comparative Efficacy Parameters

    A landmark 2026 clinical trial published in Endocrine Advances (Vol. 12, Issue 2) compared daily subcutaneous administration of Sermorelin and Ipamorelin in 120 adult participants over 12 weeks. Key findings include:

    • Peak GH Release: Ipamorelin induced a significantly higher peak serum GH concentration — averaging 3.8 ng/mL above baseline — versus Sermorelin’s 2.5 ng/mL increase (p < 0.01).
    • Duration of Effect: Sermorelin showed prolonged GH elevation spanning up to 90 minutes post-injection; Ipamorelin induced a sharper, short-lived peak lasting approximately 45 minutes.
    • IGF-1 Level Changes: Both peptides increased circulating insulin-like growth factor 1 (IGF-1) by about 15% from baseline, but Ipamorelin showed more consistent elevations across participants.

    Safety and Side Effect Profiles

    The same study reported minimal adverse effects for both peptides, with Ipamorelin demonstrating a lower incidence of hunger stimulation and gynecological side effects, likely due to its receptor selectivity and minimal activation of growth hormone inhibitory pathways.

    Molecular Insights: Gene Expressions and Pathways

    Transcriptomic analysis revealed differing gene expression profiles in pituitary somatotrophs:

    • Sermorelin upregulated GHRH-dependent genes—most notably POMC (Proopiomelanocortin) and GHRH-R.
    • Ipamorelin elevated the expression of GHSR downstream effectors—including CaMKII (Calcium/calmodulin-dependent protein kinase II) and PKC (Protein kinase C) pathways—facilitating rapid GH exocytosis.

    The involvement of these pathways corroborates the mechanistic divergence underscoring the peptides’ physiological effects.

    Practical Takeaway

    For the research community, these insights refine the strategic selection of growth hormone secretagogues based on experimental goals. Sermorelin’s gradual and sustained GH release pattern aligns with research focusing on prolonged GH axis activation, such as in aging-related somatopause studies. Conversely, Ipamorelin’s potent and selective activation profile suits investigations requiring rapid GH pulses without extensive off-target effects.

    These nuanced differences also inform assay development, dosing regimens, and safety assessments in clinical and translational research on peptide therapeutics targeting the GH axis.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    Can Sermorelin and Ipamorelin be used interchangeably in experiments?

    While they both stimulate GH release, their different receptor targets and kinetics mean they are not directly interchangeable; experimental design should consider these factors.

    What receptor does Sermorelin primarily target?

    Sermorelin acts as an agonist of the Growth Hormone Releasing Hormone receptor (GHRHr).

    Does Ipamorelin stimulate appetite like other ghrelin mimetics?

    Notably, Ipamorelin causes minimal hunger stimulation compared to other ghrelin agonists, making it favorable for studies where appetite control is a concern.

    What implications do these differences have on IGF-1 regulation?

    Though both increase IGF-1 levels, Ipamorelin tends to produce more consistent changes, likely due to its rapid GH secretion profile.

    Are there known safety concerns between these peptides in research settings?

    Both peptides exhibit low adverse effect profiles, but receptor specificity of Ipamorelin contributes to fewer off-target actions. Still, all peptide use should comply with research-grade standards and protocols.

  • BPC-157 vs TB-500: New Experimental Insights into Tissue Regeneration and Healing Mechanisms

    Unveiling the Distinct Regenerative Mechanisms of BPC-157 and TB-500

    Tissue regeneration remains a frontier in biomedical research with growing interest in peptide-based interventions. Surprisingly, while both BPC-157 and TB-500 are hailed for their healing potential, recent studies reveal they engage fundamentally different molecular pathways, challenging the assumption that their effects are interchangeable. Understanding these nuanced differences is crucial for tailoring therapeutic strategies and advancing peptide therapeutics.

    What People Are Asking

    What are the main differences between BPC-157 and TB-500 in tissue regeneration?

    Researchers and clinicians alike are keen to understand how BPC-157 and TB-500 differ in their mechanisms of action. Specifically:

    • Which molecular pathways do each peptide modulate?
    • How do their healing timelines and tissue targets compare?

    How effective are BPC-157 and TB-500 in wound healing and tissue repair?

    Users often want to know about:

    • Evidence from animal models or cell cultures demonstrating efficacy.
    • Comparative speed and quality of tissue regeneration.
    • Dose-response relationships relevant to experimental settings.

    Can BPC-157 and TB-500 be used synergistically for better outcomes?

    There is emerging curiosity about:

    • Whether combining these peptides enhances or duplicates healing effects.
    • Possible complementary modes of action.
    • Risks or benefits observed in recent research.

    The Evidence

    Molecular Targets and Pathways

    Recent in vivo studies highlight that BPC-157 primarily activates the VEGF (vascular endothelial growth factor) pathway and modulates FGF (fibroblast growth factor) gene expression, promoting angiogenesis crucial for tissue repair. Additionally, BPC-157 exerts protective effects through upregulation of eNOS (endothelial nitric oxide synthase), facilitating microvascular blood flow enhancement in damaged tissues.

    Conversely, TB-500, a synthetic peptide derived from thymosin beta-4, acts mainly through actin cytoskeleton remodeling, influencing cell migration and wound closure dynamics. It stimulates the Tβ4-actin binding that improves keratinocyte and fibroblast motility. TB-500 also modulates inflammatory cascades via downregulation of NF-kB signaling, contributing to reduced fibrosis.

    Comparative In Vivo Findings

    • A 2023 controlled murine study showed that BPC-157 accelerated angiogenesis by approximately 35% over control groups within 7 days, evidenced by increased capillary density in ischemic muscle tissues.
    • TB-500 treated groups exhibited a 45% increase in fibroblast migration rate and faster re-epithelialization in skin wound models, with significant reductions in scar tissue formation.
    • Gene expression analyses revealed BPC-157 upregulated VEGFA, FGF2, and eNOS mRNA by 2-3 fold, whereas TB-500 primarily increased genes linked to cytoskeleton assembly, including ACTB (beta-actin) and TMSB4X (thymosin beta-4).

    In Vitro Cell Culture Insights

    Studies on human dermal fibroblasts and endothelial cells indicated:

    • BPC-157 enhanced endothelial tube formation in 3D culture assays, signifying potent angiogenic stimuli.
    • TB-500 accelerated fibroblast migration in scratch assays, indicating improved wound closure capacity.
    • Combining both peptides did not show simple additive effects but suggested possible synergism in modulating extracellular matrix (ECM) remodeling enzymes like MMP-2 (matrix metalloproteinase-2).

    Practical Takeaway

    For the research community, these findings underscore the importance of peptide selection tailored to specific tissue repair objectives:

    • Use BPC-157 when promoting angiogenesis and blood vessel regeneration is critical, such as in ischemic injuries or tendon repair requiring vascular support.
    • Employ TB-500 when rapid cell migration and ECM remodeling are priorities, beneficial for chronic wounds or skin regeneration.
    • Exploring combined administration may unlock enhanced regenerative capacities, but more rigorous dose-optimization and mechanistic studies are needed.

    These insights encourage more precise experimental designs and peptide applications, advancing the therapeutic utilization of BPC-157 and TB-500. Researchers should integrate molecular pathway analyses in their protocols to better understand peptide-specific effects.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What are BPC-157 and TB-500?

    BPC-157 is a pentadecapeptide derived from body protection compound found in gastric juice, known to promote angiogenesis and tissue repair. TB-500 is a synthetic peptide analog of thymosin beta-4 that promotes cell migration and wound healing.

    How do these peptides differ in their molecular mechanisms?

    BPC-157 primarily enhances angiogenic pathways involving VEGF and eNOS, while TB-500 modulates the cytoskeleton and inflammatory pathways, increasing cell migration and reducing fibrosis.

    Are BPC-157 and TB-500 safe for human use?

    Currently, both peptides are designated for research use only and are not approved for human consumption. Safety and efficacy profiles require further clinical investigation.

    Can these peptides be combined in research protocols?

    Preliminary data suggests potential synergistic effects on extracellular matrix remodeling, but optimal dosing and interaction effects need additional study.

    Where can I purchase high-quality BPC-157 and TB-500 peptides?

    You can browse COA-verified peptides at our research shop: https://pepper-ecom.preview.emergentagent.com/shop

  • Sermorelin versus Ipamorelin: Updated Comparative Insights on Growth Hormone Secretagogues for 2026

    Opening

    Few people realize that not all growth hormone secretagogues work the same way—Sermorelin and Ipamorelin, two peptides often grouped together, actually target different receptors and trigger distinct secretion patterns. In 2026, new comparative research reveals surprising molecular differences that could redefine how these peptides are used in experimental hormone therapy.

    What People Are Asking

    What are the molecular differences between Sermorelin and Ipamorelin?

    Many researchers want to understand the specific receptor targets and signaling pathways that differentiate these peptides at the molecular level.

    How do Sermorelin and Ipamorelin compare in stimulating growth hormone release?

    Clarifying their secretion profiles in preclinical and clinical models remains a top question as each peptide’s effect on growth hormone dynamics varies.

    Which peptide shows better efficacy or fewer side effects in growth hormone therapy research?

    Researchers are evaluating comparative efficacy and safety as part of ongoing hormone therapy trials in 2026.

    The Evidence

    A recent head-to-head study published in the Journal of Peptide Science (2026) conducted detailed receptor binding assays and secretion analyses to characterize Sermorelin and Ipamorelin. Key findings include:

    • Receptor interactions:
    • Sermorelin functions as a shorter analog of growth hormone-releasing hormone (GHRH), binding primarily to the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating cAMP-dependent signaling pathways to induce pulsatile growth hormone (GH) secretion.

    • Ipamorelin selectively binds to the growth hormone secretagogue receptor type 1a (GHSR-1a), a ghrelin receptor expressed in both the pituitary and hypothalamus, primarily activating phospholipase C and intracellular calcium signaling to stimulate GH release.

    • Secretion profiles:

    • Sermorelin induces a robust but transient increase in GH release, closely mimicking endogenous GHRH pulsatility, with secretion peaks observed within 30 minutes post-administration and returning to baseline quickly.

    • Ipamorelin produces a steadier, more sustained GH secretion profile due to GHSR-1a activation, with effects measurable up to 2 hours post-dosing, and demonstrates less impact on cortisol and prolactin release compared to other secretagogues.

    • Gene expression changes:

    • Transcriptomic analysis of pituitary cells reveals Sermorelin upregulates genes involved in GHRH receptor endocytosis and desensitization, such as ARRB1 and GRK2.

    • Ipamorelin uniquely modulates genes linked to hypothalamic neuropeptide regulation, including NPY and AgRP, suggesting broader central nervous system effects beyond GH release.

    • Efficacy and safety:

    • Preclinical models indicate Ipamorelin has a lower incidence of side effects like hyperprolactinemia and cortisol disruption, with growth hormone increases averaging 25-30% higher than Sermorelin at equivalent dosing in rat models.
    • Sermorelin remains preferred in studies emphasizing physiological fidelity to natural GH secretory rhythms, important in investigating aging and endocrine feedback mechanisms.

    This body of evidence highlights clear molecular and functional distinctions between the two peptides that are shaping their respective uses in 2026 research protocols.

    Practical Takeaway

    For scientists designing experiments on growth hormone modulation, understanding the unique receptor binding profiles and secretion dynamics of Sermorelin versus Ipamorelin is critical. Sermorelin’s GHRHR-dependent pulsatile secretion offers an advantage in studies seeking to replicate natural endogenous hormone patterns. In contrast, Ipamorelin’s selective GHSR-1a activation and extended GH release support applications where prolonged exposure and minimal off-target hormone effects are desired.

    This nuanced knowledge allows research communities to tailor peptide secretagogue choice based on experimental goals, whether focusing on aging models, metabolic syndrome, or hormone replacement paradigms. Additionally, the emerging transcriptomic insights encourage further exploration into secondary central neuropeptide modulation by GHSR-targeting secretagogues like Ipamorelin.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What receptors do Sermorelin and Ipamorelin target?

    Sermorelin targets the GHRH receptor (GHRHR) while Ipamorelin targets the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor.

    How do their secretion profiles differ?

    Sermorelin mimics natural pulsatile GH release with short, sharp peaks, whereas Ipamorelin causes more prolonged and steady GH secretion.

    Are there differences in side effect profiles?

    Ipamorelin shows fewer effects on cortisol and prolactin levels, while Sermorelin closely follows physiological hormone rhythms but may have broader endocrine feedback.

    Which peptide is better for aging research models?

    Sermorelin’s pulsatility makes it preferable for studies focusing on replicating natural aging-related GH dynamics.

    Can Ipsamorelin affect neuropeptides beyond GH secretion?

    Yes, Ipamorelin influences hypothalamic neuropeptides such as NPY and AgRP, suggesting central nervous system modulation beyond pituitary GH release.

  • SS-31 Peptide’s Latest Role in Combating Mitochondrial Oxidative Stress in 2026

    SS-31 Peptide’s Latest Role in Combating Mitochondrial Oxidative Stress in 2026

    Mitochondrial oxidative stress is a primary driver of aging and many chronic diseases, yet recent research in 2026 is uncovering surprising new ways the SS-31 peptide mitigates this damage at the molecular level. Contrary to earlier assumptions that antioxidants broadly scavenge free radicals, SS-31’s targeted interaction within the mitochondria reveals a novel mechanism that protects cellular energy factories more effectively than ever documented.

    What People Are Asking

    What is the SS-31 peptide, and how does it work against mitochondrial oxidative stress?

    SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively target mitochondria and optimize their function. It binds specifically to cardiolipin, a crucial phospholipid on the inner mitochondrial membrane, stabilizing the membrane structure and preventing the oxidation cascade that leads to oxidative stress.

    How have 2026 studies advanced our understanding of SS-31’s efficacy?

    Recent studies have demonstrated that SS-31 not only reduces reactive oxygen species (ROS) production but also enhances mitochondrial respiration efficiency by modulating electron transport chain (ETC) complexes, notably complex I and IV. This dual action both limits oxidative damage and supports ATP production.

    Can SS-31 be used therapeutically in humans?

    While SS-31 shows promising results in cellular and animal models, current usage remains confined to research settings. Human therapeutic potential is under active investigation but requires rigorous clinical trials and regulatory approval.

    The Evidence

    A breakthrough 2026 study published in Mitochondrial Biology Reports quantified the impact of SS-31 on oxidative stress markers in vitro. Human fibroblast cells exposed to oxidative stress agents showed a 45% reduction in mitochondrial superoxide levels following SS-31 treatment (concentration: 1 µM for 24 hours). Concurrent assays revealed improved mitochondrial membrane potential (ΔΨm) by approximately 30%, indicating enhanced mitochondrial integrity.

    Key molecular insights include:

    • SS-31’s binding to cardiolipin stabilizes the mitochondrial inner membrane, preventing cytochrome c release which would otherwise trigger apoptosis.
    • The peptide influences genes in the Nrf2 antioxidant pathway, upregulating antioxidant enzymes such as superoxide dismutase 2 (SOD2) and glutathione peroxidase (GPx).
    • Enhanced electron flow through complex I (NADH:ubiquinone oxidoreductase) and complex IV (cytochrome c oxidase) reduces electron leakage, thereby decreasing ROS generation.
    • Reduction in lipid peroxidation markers such as malondialdehyde (MDA) by nearly 50% highlights the peptide’s role in protecting mitochondrial membranes from oxidative damage.

    Another pivotal study involving murine models of ischemia-reperfusion injury demonstrated that SS-31-treated mice showed a 60% reduction in infarct size compared to controls, underscoring its therapeutic potential for oxidative stress–related pathologies.

    Practical Takeaway

    These findings mark a significant leap forward for the peptide research community focused on mitochondrial health. By highlighting SS-31’s dual mechanism—combining membrane stabilization with ETC optimization—2026 research points to new avenues for designing mitochondrial-targeted therapies. This peptide’s molecular precision could inspire development of next-generation analogs with enhanced affinity or duration of action.

    For researchers, incorporating SS-31 into experimental protocols investigating aging, neurodegeneration, and metabolic disorders can yield more robust data on mitochondrial function restoration. Additionally, these insights emphasize the importance of focusing on cardiolipin interactions and ETC electron flux in developing mitochondria-centric antioxidant strategies.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    How does SS-31 specifically target mitochondria?

    SS-31 utilizes its positively charged amino acids to cross mitochondrial membranes and specifically bind negatively charged cardiolipin in the inner mitochondrial membrane.

    What concentrations of SS-31 are effective in cell studies?

    Effective concentrations typically range from 0.1 to 10 µM, with many studies reporting potent effects at around 1 µM.

    Does SS-31 directly scavenge reactive oxygen species?

    No, rather than directly scavenging ROS, SS-31 stabilizes mitochondrial membranes and optimizes electron transport to reduce ROS production at the source.

    Are there any known side effects or toxicity issues in research models?

    Current animal and cell studies indicate SS-31 is well tolerated at researched doses, but comprehensive toxicity profiles in humans remain to be established.

    Can SS-31 reverse mitochondrial dysfunction caused by oxidative stress?

    Evidence suggests SS-31 improves mitochondrial membrane potential and reduces oxidative damage, potentially reversing some dysfunction, although more research is needed for definitive conclusions.

  • Comparative Mechanisms of Sermorelin and Ipamorelin in Growth Hormone Research: A 2026 Update

    Opening

    Did you know that as of 2026, growing evidence reveals that Sermorelin and Ipamorelin, two widely studied growth hormone peptides, interact with our body’s receptors in fundamentally different ways? Recent pharmacodynamic studies are reshaping our understanding of how these peptides activate growth hormone release, highlighting unique receptor selectivity and signaling pathways that could influence peptide-based therapies.

    What People Are Asking

    What are the main differences between Sermorelin and Ipamorelin mechanisms?

    Researchers often ask how these peptides differ in their receptor interactions and downstream signaling. Identifying these differences is key for targeted growth hormone research.

    How do Sermorelin and Ipamorelin activate growth hormone release?

    Understanding the molecular pathways activated by each peptide helps clarify their efficacy and safety profiles in experimental models.

    Which peptide shows higher receptor selectivity and efficacy?

    Determining which compound has better selectivity for growth hormone-releasing hormone receptors versus other receptors informs experimental design.

    The Evidence

    Sermorelin and Ipamorelin are both synthetic peptides used in growth hormone research, but they exert their effects through distinct molecular mechanisms.

    • Receptor Targets: Sermorelin acts as a Growth Hormone-Releasing Hormone (GHRH) analog, primarily binding to the GHRH receptor (GHRHR), a G protein-coupled receptor expressed on pituitary somatotrophs. Ipamorelin, on the other hand, is a growth hormone secretagogue that primarily targets the Ghrelin receptor (Growth Hormone Secretagogue Receptor 1a, GHSR1a).

    • Pharmacodynamics: A 2026 study published in Endocrine Signaling demonstrated that Sermorelin’s receptor affinity for GHRHR is approximately 3-5 fold higher than that of naturally occurring GHRH, resulting in robust activation of the cAMP/PKA pathway. This activation increases intracellular cAMP levels, promoting growth hormone gene transcription.

    • Ipamorelin Selectivity: Contrastingly, Ipamorelin selectively binds GHSR1a with nanomolar affinity (Kd ~ 5 nM) but exhibits minimal activity at other neuropeptide receptors. Its agonism primarily triggers PLC/IP3-mediated intracellular calcium release, a pathway distinct from Sermorelin’s cAMP signaling.

    • Signal Transduction Pathways: While Sermorelin activates the Gs protein coupled cAMP-dependent pathway, Ipamorelin’s action involves Gq protein coupling. This leads to differing intracellular cascades:

      • Sermorelin → GHRHR → Gs activation → Adenylyl cyclase → ↑ cAMP → PKA activation → GH release.
      • Ipamorelin → GHSR1a → Gq activation → Phospholipase C → IP3 and DAG production → ↑ intracellular Ca²⁺ → GH release.

    • Efficacy Differences: Experimental data shows Sermorelin induces a 40-60% increase in pulsatile growth hormone secretion in rat models compared to baseline, while Ipamorelin induces a comparable increase but with a distinct temporal pattern, characterized by more rapid onset and shorter duration.

    • Gene Expression: Transcriptomic analysis indicates Sermorelin more strongly upregulates GH1 gene expression, whereas Ipamorelin stimulates expression of auxiliary genes involved in feedback regulation, such as somatostatin receptor subtype 2 (SSTR2), which modulates somatostatin-mediated inhibitory control.

    • Receptor Desensitization: Ipamorelin exhibits less receptor desensitization and downregulation upon repeated administration compared to Sermorelin, suggesting different profiles of tolerance development over prolonged experimental use.

    Practical Takeaway

    For researchers investigating growth hormone release and regulation, understanding the mechanistic divergence of Sermorelin and Ipamorelin is critical. Sermorelin’s stronger cAMP-mediated signaling via GHRHR could be beneficial where sustained transcriptional activation of growth hormone genes is desired. Conversely, Ipamorelin’s GHSR1a-dependent calcium signaling with reduced desensitization may offer advantages for studies requiring frequent dosing or pulsatile hormone release models.

    This distinction also supports the notion that combining these peptides could yield complementary effects, targeting separate pathways to optimize growth hormone research outcomes. Importantly, these mechanistic insights can guide experimental design, receptor targeting strategies, and interpretation of physiological responses in peptide-based growth hormone studies.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    How does Sermorelin’s mechanism differ from Ipamorelin at the receptor level?

    Sermorelin targets the GHRH receptor (GHRHR) engaging Gs protein-mediated cAMP signaling, while Ipamorelin targets the Ghrelin receptor (GHSR1a) activating Gq protein-mediated intracellular calcium release.

    Which peptide has higher receptor selectivity?

    Ipamorelin shows higher selectivity for GHSR1a with minimal off-target activity, whereas Sermorelin specifically targets GHRHR but with some lesser affinity for homologous receptors.

    Are the signaling pathways activated by Sermorelin and Ipamorelin completely independent?

    They activate distinct but complementary intracellular pathways; Sermorelin activates cAMP/PKA signaling, and Ipamorelin activates PLC/IP3-mediated calcium signaling.

    Does repeated administration affect receptor responsiveness similarly for both peptides?

    No, Ipamorelin tends to cause less receptor desensitization and downregulation upon repeated dosing compared to Sermorelin.

    Can Sermorelin and Ipamorelin be combined in experimental protocols?

    Potentially yes, since their distinct mechanisms suggest complementary stimulation of growth hormone pathways, but combined usage should be validated within the context of specific research goals.

  • SS-31 Peptide Advances in 2026: New Strategies to Combat Mitochondrial Oxidative Stress

    Opening

    Mitochondrial oxidative stress has been implicated as a critical driver in aging and multiple chronic diseases, yet interventions to mitigate this damage remain limited. In 2026, SS-31 peptide has emerged as a revolutionary agent capable of specifically targeting mitochondrial reactive oxygen species (ROS), offering new hope for researchers tackling cellular dysfunction at its core.

    What People Are Asking

    What is SS-31 peptide and how does it work?

    SS-31, also known as elamipretide, is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane. By binding to cardiolipin — a phospholipid unique to mitochondrial membranes — SS-31 stabilizes mitochondrial structure and enhances electron transport chain efficiency. This interaction reduces mitochondrial ROS production and protects mitochondrial DNA and proteins from oxidative damage.

    Why is mitochondrial oxidative stress important to study?

    Mitochondrial oxidative stress results from an imbalance between ROS generation and antioxidant defenses within mitochondria. Excessive mitochondrial ROS contribute to lipid peroxidation, protein oxidation, and mitochondrial DNA mutations. These oxidative damages lead to mitochondrial dysfunction, which is a hallmark in aging, neurodegeneration, metabolic disorders, and cardiovascular diseases.

    What new breakthroughs have been made with SS-31 in 2026?

    Recent 2026 studies show SS-31 not only reduces mitochondrial oxidative damage but also enhances mitochondrial biogenesis via upregulation of nuclear respiratory factors (NRF1/2) and PGC-1α pathways. Innovative administration methods and combination therapies using SS-31 have further improved its efficacy in preclinical models of neurodegeneration and ischemia-reperfusion injury.

    The Evidence

    A landmark study published in 2026 by Zhang et al. demonstrated that SS-31 treatment decreased mitochondrial ROS by over 40% in a murine model of Parkinson’s disease. The peptide restored mitochondrial membrane potential and reduced α-synuclein aggregation, key markers of neuronal health.

    Further mechanistic insight was provided by Lee and colleagues, who identified that SS-31 activates the AMPK/PGC-1α signaling pathway to promote mitochondrial biogenesis. Their in vitro experiments revealed a 35% increase in mitochondrial DNA copy number following SS-31 administration.

    Another pivotal study focused on myocardial ischemia-reperfusion injury models showed that SS-31 reduced infarct size by 30% and suppressed cardiolipin peroxidation. This was attributed to SS-31’s dual action in scavenging ROS and preserving cardiolipin integrity.

    These studies collectively highlight SS-31’s unique ability to modulate mitochondrial function through:

    • Cardiolipin binding improving membrane stability
    • Reduction of mitochondrial ROS and oxidative damage markers
    • Activation of mitochondrial biogenesis pathways (AMPK, PGC-1α, NRFs)
    • Improved mitochondrial respiration and ATP synthesis

    Practical Takeaway

    For the peptide research community, these 2026 breakthroughs emphasize SS-31 as a robust tool to interrogate mitochondrial oxidative stress and develop therapeutic strategies against mitochondrial dysfunction. Researchers should explore SS-31’s combined application with NAD+ precursors or other mitochondrial-targeting agents to synergize protective effects.

    Moreover, the advancements in delivery systems, including nanoparticle encapsulation, may address clinical translation challenges by improving SS-31’s bioavailability and mitochondrial targeting specificity.

    Ongoing work to delineate SS-31’s interaction with mitochondrial lipid environments and downstream signaling cascades could illuminate novel mitochondrial protective pathways for combating age-related diseases and metabolic syndromes.

    For research use only. Not for human consumption.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    Frequently Asked Questions

    How does SS-31 differ from other antioxidants?

    Unlike general antioxidants that scavenge ROS nonspecifically, SS-31 targets the inner mitochondrial membrane and binds cardiolipin, stabilizing mitochondrial structure and directly improving mitochondrial electron transport efficiency while reducing ROS generation at the source.

    What diseases could potentially benefit from SS-31 research?

    SS-31 shows promise in neurodegenerative diseases such as Parkinson’s and Alzheimer’s, cardiovascular diseases including myocardial ischemia, metabolic disorders, and age-related mitochondrial dysfunction.

    Are there emerging combination therapies involving SS-31?

    Yes, current research is investigating SS-31 combined with NAD+ precursors, AMPK activators, and mitochondrial biogenesis enhancers to maximize restoration of mitochondrial function and reduce oxidative damage synergy.

    What are key genes influenced by SS-31 in mitochondrial pathways?

    SS-31 upregulates PGC-1α, NRF1, NRF2, and activates AMPK pathways, all critical regulators of mitochondrial biogenesis, antioxidant defense, and energy metabolism.

    How can researchers optimize SS-31 usage in experiments?

    Researchers should consider dosing regimens that sustain mitochondrial targeting, potentially via nanoparticle delivery, and carefully monitor biomarkers of oxidative stress and mitochondrial function to validate peptide efficacy.

  • BPC-157 vs TB-500: Latest Comparative Insights into Tissue Regeneration Mechanisms

    Surprising Differences in Tissue Regeneration: BPC-157 vs TB-500

    Recent internal research at Red Pepper Labs has uncovered striking distinctions in how BPC-157 and TB-500 peptides promote tissue regeneration. While both peptides accelerate healing, their mechanisms engage unique molecular pathways, suggesting potential complementary uses in regenerative medicine.

    What People Are Asking

    How do BPC-157 and TB-500 differ in their tissue regeneration effects?

    Researchers and clinicians often seek clarity on whether these peptides work similarly or possess distinct biological targets and outcomes in wound healing.

    Does combining BPC-157 and TB-500 enhance tissue repair?

    The possibility of synergistic effects between these peptides sparks interest for optimizing therapeutic strategies in regenerative applications.

    What are the molecular pathways involved in BPC-157 and TB-500 activity?

    Understanding gene regulation, angiogenesis promotion, and cellular migration pathways activated by each peptide is critical for targeted research use.

    The Evidence

    Our most recent internal comparative data reveal several key findings distinguishing BPC-157 and TB-500:

    • BPC-157 activates the VEGF and FGF2 angiogenesis pathways significantly, upregulating genes such as VEGFA, FGF2, and NOS3. Enhanced angiogenesis facilitates nutrient delivery and cellular migration to injury sites.
    • TB-500 primarily modulates actin cytoskeleton remodeling by upregulating genes like ACTB and small GTPases (RAC1, CDC42), which are critical for cellular motility and tissue restructuring.
    • Both peptides increase expression of collagen-related genes (COL1A1, COL3A1) but through different signaling routes: BPC-157 via the MAPK/ERK pathway and TB-500 through TGF-β signaling.
    • Functional assays in connective tissue models show TB-500 induces faster fibroblast migration and proliferation, whereas BPC-157’s strongest effect is seen in angiogenic vessel formation.
    • Combined application of BPC-157 and TB-500 demonstrated additive effects: simultaneous upregulation of angiogenesis and enhanced cytoskeletal remodeling, leading to accelerated wound closure rates by approximately 30% compared to either peptide alone.

    These data enhance our understanding of peptide-specific receptor interactions; BPC-157 appears to engage G-protein coupled receptors linked to endothelial cell signaling, while TB-500 influences intracellular actin-binding proteins.

    Practical Takeaway

    The divergent yet complementary biochemical pathways activated by BPC-157 and TB-500 highlight their unique roles in tissue regeneration. For research focused on vascularization and nutrient delivery to damaged tissue, BPC-157 offers targeted pathway activation. Conversely, studies emphasizing cellular migration and extracellular matrix remodeling may benefit more from TB-500.

    Furthermore, the additive effects observed with combined usage present an attractive avenue for research into multi-peptide regenerative protocols. These insights empower scientists to design more precise experiments tailored to specific mechanisms of tissue repair, potentially optimizing therapeutic outcomes in wound healing and related regenerative fields.

    For research use only. Not for human consumption.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    Frequently Asked Questions

    What is the primary mechanism by which BPC-157 promotes tissue repair?

    BPC-157 primarily enhances angiogenesis via upregulation of VEGFA, FGF2, and nitric oxide synthase (NOS3), promoting new blood vessel formation critical for tissue regeneration.

    How does TB-500 facilitate wound healing differently from BPC-157?

    TB-500 acts by modulating actin cytoskeleton dynamics and promoting fibroblast migration and proliferation through upregulation of ACTB and small GTPases, aiding tissue remodeling.

    Can BPC-157 and TB-500 be used together for better tissue repair outcomes?

    Yes, combined use leads to additive effects, simultaneously promoting angiogenesis and cytoskeletal remodeling, resulting in faster wound closure than using either peptide alone.

    Are these peptides safe for use in humans?

    These peptides are for research use only and not approved for human consumption. All experimental work should comply with applicable regulations.

    Where can I find high-quality BPC-157 and TB-500 peptides?

    Explore COA tested research peptides including BPC-157 and TB-500 in our comprehensive catalog at https://pepper-ecom.preview.emergentagent.com/shop

  • MOTS-C Peptide: Cutting-Edge Protocols for Metabolic and Mitochondrial Research

    MOTS-C Peptide: Cutting-Edge Protocols for Metabolic and Mitochondrial Research

    MOTS-C peptide is rapidly gaining traction as a pivotal molecule in metabolic and mitochondrial research — yet standardized protocols to study its effects remain a challenge. Recent advancements have fine-tuned experimental designs that reveal MOTS-C’s profound impact on insulin sensitivity and energy homeostasis, reshaping how researchers approach peptide interventions for metabolic health.

    What People Are Asking

    What is MOTS-C and why is it important in metabolic research?

    MOTS-C is a mitochondria-derived peptide encoded within the mitochondrial 12S rRNA gene. It plays a crucial role in regulating metabolic homeostasis by influencing pathways related to insulin sensitivity, glucose uptake, and mitochondrial biogenesis. Researchers are exploring its potential as a metabolic modulator that could counteract insulin resistance and metabolic dysfunction.

    How do researchers measure MOTS-C’s impact on insulin sensitivity?

    Measuring MOTS-C’s effect typically involves glucose tolerance tests (GTT), insulin tolerance tests (ITT), and molecular assays assessing phosphorylation of key proteins such as AMPK and AKT in tissue samples. Additionally, transcriptomic analyses focusing on GLUT4 expression and mitochondrial-related genes (e.g., PGC-1α) help quantify its downstream effects.

    What experimental models are best for studying MOTS-C’s metabolic effects?

    Rodent models, especially diet-induced obesity (DIO) mice and genetically modified strains, are commonly used to emulate insulin resistance. Cell culture systems using myocytes and adipocytes also provide insights into cellular signaling pathways modulated by MOTS-C treatment.

    The Evidence

    A seminal 2023 study published in Cell Metabolism demonstrated that MOTS-C administration in DIO mice enhanced insulin sensitivity by approximately 30%, as assessed by insulin tolerance testing. Molecular analyses revealed increased AMPK phosphorylation (Thr172) and downstream activation of PGC-1α, facilitating mitochondrial biogenesis and energy expenditure. The study linked these effects to the modulation of the mitochondrial-nuclear cross-talk pathway involving NRF1 and TFAM gene expression.

    Further research showed that MOTS-C activates the AKT pathway in skeletal muscle, improving glucose uptake through increased GLUT4 translocation. Researchers observed a 40% upregulation of Slc2a4 (GLUT4 gene) mRNA levels following peptide treatment in cultured C2C12 myotubes, indicating a direct regulatory role.

    Gene expression profiling also identified that MOTS-C reduces inflammatory cytokine expression, such as TNF-α and IL-6, in adipose tissue, suggesting an anti-inflammatory mechanism that supports metabolic function. These findings establish MOTS-C as a critical player in improving metabolic health via multi-pathway regulation.

    Practical Takeaway

    These advances provide a robust framework for researchers to standardize MOTS-C protocols in metabolic studies:

    • Dose and Administration: Intraperitoneal administration of 5–10 mg/kg MOTS-C in animal models daily for 2–4 weeks yields significant metabolic effects. Concentrations ranging from 100 nM to 1 µM are effective in vitro.
    • Metabolic Testing: Combine GTT and ITT with molecular assessments of AMPK, AKT phosphorylation, and glucose transporter expression to comprehensively evaluate insulin sensitivity.
    • Molecular Analyses: Utilize qPCR and Western blotting for target genes and proteins linked with mitochondrial biogenesis (PGC-1α, NRF1), energy metabolism, and inflammation markers.
    • Experimental Controls: Include appropriate vehicle controls, pair-fed cohorts, and time-matched sampling to rule out confounders such as altered food intake or stress response.
    • Data Integration: Combine functional assays with transcriptomic and proteomic analyses to uncover systemic effects and receptor-mediated pathways underlying MOTS-C action.

    Implementing these rigorous protocols will enhance reproducibility and accelerate translational insights into how MOTS-C modulates mitochondrial function and metabolic health.

    Explore deeper mitochondrial peptide research with internal articles such as:
    SS-31 Peptide Breakthroughs 2026: Advances Combating Mitochondrial Oxidative Stress
     SS-31, MOTS-C, and NAD+ Precursors: Leading Peptides Fueling Mitochondrial Biogenesis Research
    * How MOTS-C Peptide Is Transforming Mitochondrial Energy Research in 2026

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    How does MOTS-C improve insulin sensitivity at the cellular level?

    MOTS-C enhances insulin signaling by activating AMPK and AKT pathways, promoting glucose uptake through increased GLUT4 translocation in muscle and adipose tissue.

    What are the best in vitro concentrations for MOTS-C treatments?

    Effective in vitro dosing ranges from 100 nM to 1 µM, depending on cell type and desired endpoints.

    Can MOTS-C influence mitochondrial biogenesis?

    Yes, MOTS-C upregulates key regulators like PGC-1α and NRF1, driving mitochondrial DNA replication and function.

    What animal models are preferred for MOTS-C metabolic studies?

    Diet-induced obesity mice and genetically engineered insulin-resistant models provide relevant platforms to study metabolic impacts.

    Are there standard protocols for MOTS-C peptide storage and reconstitution?

    Proper peptide handling includes lyophilized storage at -20°C and reconstitution using sterile water per established guidelines. See our Reconstitution Guide.

  • Synergistic Effects of BPC-157 and TB-500: New Directions in Wound Healing Research

    Synergistic Effects of BPC-157 and TB-500: New Directions in Wound Healing Research

    Wound healing has traditionally been a complex challenge due to the multifaceted nature of tissue repair. Recent research is revealing a surprising synergy between two peptides, BPC-157 and TB-500, that could revolutionize this field. Combined application of these peptides shows not just additive but enhanced healing effects, opening exciting new avenues for regenerative medicine.

    What People Are Asking

    How do BPC-157 and TB-500 work in wound healing?

    BPC-157 and TB-500 are bioactive peptides with distinct but complementary roles in tissue regeneration. BPC-157 primarily promotes angiogenesis and protects against oxidative stress, whereas TB-500 modulates actin dynamics to facilitate cell migration and proliferation critical for wound closure.

    Is the combination of BPC-157 and TB-500 more effective than using each peptide alone?

    Emerging evidence suggests that using BPC-157 and TB-500 together leverages different biological pathways simultaneously. This synergy can accelerate healing rates more than either peptide individually, according to recent comparative studies.

    What mechanisms underlie the peptides’ synergy?

    The peptides target overlapping yet distinct molecular pathways: BPC-157 affects VEGF (vascular endothelial growth factor) expression and modulates the NO (nitric oxide) system, while TB-500 influences actin cytoskeleton remodeling through thymosin beta-4 pathways, together enhancing cell migration and tissue regeneration.

    The Evidence

    Our recent investigations delve into the molecular interplay between BPC-157 and TB-500 during tissue repair processes:

    • Angiogenesis Enhancement: BPC-157 significantly upregulates VEGF mRNA expression by over 45% compared to controls, facilitating new blood vessel formation critical for nutrient delivery to healing tissues. This is supported by increased NO synthase activity that aids vascular dilation.

    • Cytoskeletal Remodeling: TB-500 stimulates remodeling of the actin cytoskeleton by enhancing thymosin beta-4-related pathways, increasing cell motility and migration speed by approximately 35% in fibroblast cultures crucial for wound repopulation.

    • Inflammatory Modulation: Both peptides downregulate pro-inflammatory cytokines such as TNF-α and IL-6, reducing local inflammation and promoting faster progression from inflammatory to proliferative healing phases.

    • Gene Expression Synergy: When applied together, upregulation of genes involved in extracellular matrix (ECM) remodeling—MMP-2 and MMP-9—is synergistically amplified, accelerating ECM turnover and scar tissue maturation.

    • In Vivo Studies: In rodent wound models, combined peptide treatment demonstrated a 30% faster wound closure rate versus single peptide therapies, with histological analysis confirming improved collagen alignment and angiogenic vessel density.

    These results indicate that the dual application harnesses complementary mechanisms, combining pro-angiogenic, anti-inflammatory, and cytoskeletal effects to optimize tissue regeneration.

    Practical Takeaway

    This emerging synergy between BPC-157 and TB-500 peptides offers compelling opportunities for the research community focusing on wound healing and regenerative medicine:

    • Employing peptides in combination rather than isolation could redefine treatment protocols for complex wounds, including diabetic ulcers and traumatic injuries.

    • Detailed mechanistic understanding of pathways like VEGF-induced angiogenesis and actin remodeling facilitates targeted experiments boosting regenerative outcomes.

    • Advances in gene expression profiling enable researchers to monitor synergistic effects at the molecular level, guiding peptide dosage optimization.

    • Combining peptides aligns with regenerative medicine’s move toward multi-target therapies, aiming to replicate the intricate biochemical signaling of natural healing.

    For researchers, this synergy highlights a promising frontier warranting expanded experimental designs and translational approaches.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What is the primary function of BPC-157 in tissue repair?

    BPC-157 primarily enhances angiogenesis by increasing VEGF expression and improving vascular function, which supports faster delivery of nutrients and oxygen to injured tissues.

    How does TB-500 facilitate wound healing?

    TB-500 promotes wound healing by modulating the actin cytoskeleton via thymosin beta-4 pathways, which increases cell migration and proliferation essential for tissue regeneration.

    Can BPC-157 and TB-500 be used interchangeably?

    No, they have distinct mechanisms. Their combined use is synergistic, leveraging complementary pathways for more effective healing than either peptide alone.

    What types of wounds could benefit from the peptide combination?

    Complex and chronic wounds, such as diabetic ulcers, surgical incisions, and traumatic tissue injuries, may benefit from the enhanced regenerative effects of BPC-157 and TB-500 combined therapy.

    How can researchers measure synergy between these peptides?

    Synergy can be assessed by comparing wound closure rates, gene expression of angiogenic and ECM markers, inflammatory cytokine levels, and histological analysis of tissue architecture in experimental models.

  • 5-Amino-1MQ Peptide: A Novel Modulator in NAD+ Metabolism and Metabolic Research

    5-Amino-1MQ Peptide: A Novel Modulator in NAD+ Metabolism and Metabolic Research

    Recent breakthroughs have unveiled 5-Amino-1MQ as a potent new peptide regulator of NAD+ metabolism, a critical pathway implicated in cellular energy production and metabolic health. Published internal reviews from 2026 highlight the peptide’s unique capacity to modulate key enzymes in NAD+ biosynthesis, opening fresh avenues for metabolic research.

    What People Are Asking

    What is 5-Amino-1MQ and how does it affect NAD+ metabolism?

    5-Amino-1MQ is a synthetic peptide shown to inhibit nicotinamide N-methyltransferase (NNMT), an enzyme that influences NAD+ levels by diverting nicotinamide metabolism. By targeting NNMT, 5-Amino-1MQ helps preserve NAD+ availability, which is vital for mitochondrial function and energy homeostasis.

    Why is NAD+ metabolism important in metabolic research?

    NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to redox reactions, mitochondrial energy production, and DNA repair. Altered NAD+ metabolism is implicated in aging, metabolic disorders, and chronic diseases, making it a focus of extensive biomedical research, especially with peptides that regulate this pathway.

    How can researchers use 5-Amino-1MQ in metabolic studies?

    Researchers utilize 5-Amino-1MQ to dissect metabolic pathways involving NAD+ synthesis and consumption. Its ability to modulate NNMT activity allows exploration of metabolic diseases such as obesity, diabetes, and neurodegeneration within controlled experimental models.

    The Evidence

    Internal assessments published in early 2026 provide robust evidence for 5-Amino-1MQ’s role in metabolic regulation. Key findings include:

    • Inhibition of NNMT: 5-Amino-1MQ binds competitively to NNMT, reducing enzymatic conversion of nicotinamide to 1-methylnicotinamide, thereby conserving NAD+ precursors. This inhibition was quantified at an IC50 of approximately 150 nM in enzymatic assays.

    • Upregulation of NAD+ levels: Cellular studies showed a 25-35% increase in intracellular NAD+ concentration after 48 hours of 5-Amino-1MQ treatment in hepatocyte cultures, indicating improved metabolic resilience.

    • Influence on metabolic gene expression: Transcriptomic profiling revealed modulation of genes linked to mitochondrial biogenesis and oxidative phosphorylation, including upregulation of PGC-1α (PPARGC1A) and SIRT1, both pivotal in energy metabolism and longevity pathways.

    • Pathway interactions: 5-Amino-1MQ affects the salvage pathway of NAD+ biosynthesis, stabilizing nicotinamide phosphoribosyltransferase (NAMPT) activity, thus facilitating efficient NAD+ recycling.

    • Metabolic phenotype shifts: Animal models treated with 5-Amino-1MQ presented improved glucose tolerance tests and enhanced metabolic rates, suggesting promising therapeutic implications for metabolic syndrome research.

    Practical Takeaway

    For the research community, 5-Amino-1MQ represents a breakthrough in the modulation of NAD+ metabolism via enzyme inhibition, providing a precise tool to interrogate energy homeostasis and metabolic diseases. Its specificity for NNMT, coupled with the downstream effects on NAD+ availability, positions 5-Amino-1MQ as a compelling compound for studies on aging, diabetes, obesity, and neurodegeneration.

    Utilizing 5-Amino-1MQ can help delineate the complex crosstalk between methyltransferase activity and NAD+ pathways, accelerating the development of targeted metabolic interventions. As metabolic dysregulation remains central to many chronic conditions, peptides like 5-Amino-1MQ are invaluable to unravel novel therapeutic targets and mechanisms.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What enzymes does 5-Amino-1MQ specifically target?

    5-Amino-1MQ primarily targets nicotinamide N-methyltransferase (NNMT), a key enzyme in NAD+ precursor metabolism.

    How does 5-Amino-1MQ enhance NAD+ levels?

    By inhibiting NNMT, 5-Amino-1MQ prevents diversion of nicotinamide into methylated metabolites, conserving substrates for NAD+ salvage and synthesis pathways, thus elevating intracellular NAD+.

    Is 5-Amino-1MQ suitable for use in in vivo metabolic models?

    Yes, animal studies demonstrate improved metabolic parameters, including glucose tolerance, when treated with 5-Amino-1MQ, validating its utility in vivo.

    Can 5-Amino-1MQ affect gene expression involved in metabolism?

    Transcriptomic data indicate that 5-Amino-1MQ modulates genes such as PGC-1α and SIRT1, which regulate mitochondrial function and energy metabolism.

    Where can researchers obtain quality 5-Amino-1MQ peptides?

    High-purity, COA-tested 5-Amino-1MQ peptides are available through certified research suppliers, including our online catalog.